These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21822826)

  • 1. Targeted drug therapies and cancer.
    Yim KL; Cunningham D
    Recent Results Cancer Res; 2011; 185():159-71. PubMed ID: 21822826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tyrosine kinase inhibitor-induced macrocytosis.
    Schallier D; Trullemans F; Fontaine C; Decoster L; De Greve J
    Anticancer Res; 2009 Dec; 29(12):5225-8. PubMed ID: 20044640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
    Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N
    J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracranial metastasis from pediatric GI stromal tumor.
    Jagannathan JP; Ramaiya NH; Shinagare AB; Hornick JL; George S
    J Clin Oncol; 2012 Apr; 30(10):e122-5. PubMed ID: 22370323
    [No Abstract]   [Full Text] [Related]  

  • 6. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
    Deslandres M; Sibaud V; Chevreau C; Delord JP
    Ann Dermatol Venereol; 2008 Jan; Spec No 1():16-24. PubMed ID: 18342113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapeutic agents and the skin: An update.
    Heidary N; Naik H; Burgin S
    J Am Acad Dermatol; 2008 Apr; 58(4):545-70. PubMed ID: 18342708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adverse effects of new oncologic therapies].
    Weisshaupt Ch; Budak K; Pestalozzi B
    Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
    [No Abstract]   [Full Text] [Related]  

  • 10. [Molecular targets in colon cancer].
    Borner MM
    Ther Umsch; 2006 Apr; 63(4):243-8. PubMed ID: 16689454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeted therapies and their indications in solid neoplasias].
    Dreyer C; Raymond E; Faivre S
    Rev Med Interne; 2009 May; 30(5):416-24. PubMed ID: 19299048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib--a breakthrough in the treatment of gastrointestinal stromal tumors (GIST)].
    Larsen JB
    Ugeskr Laeger; 2003 Sep; 165(37):3503-7. PubMed ID: 14531349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM; Chinchilli VM; Lynch CJ; Koszyk-Szewczyk A; Gingrich R; Sivik J; Drabick JJ
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
    Hagymási K; Tulassay Z
    Orv Hetil; 2010 Oct; 151(43):1763-8. PubMed ID: 20940115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of pathologists in the target therapy of gastrointestinal tumors].
    Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2010 Jul; 39(7):433-5. PubMed ID: 21055169
    [No Abstract]   [Full Text] [Related]  

  • 16. [Targeted therapy - point blank or single shot].
    Rübben H
    Urologe A; 2008 Oct; 47(10):1297. PubMed ID: 18682912
    [No Abstract]   [Full Text] [Related]  

  • 17. [Molecular targeted therapy for malignant brain tumors].
    Okamura T; Kurisu K
    Nihon Rinsho; 2005 Sep; 63 Suppl 9():520-6. PubMed ID: 16201575
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of target agents: challenges and opportunities.
    Ardizzoni A; Tiseo M
    J Thorac Oncol; 2007 May; 2(5 Suppl):S4-6. PubMed ID: 17457232
    [No Abstract]   [Full Text] [Related]  

  • 19. A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST.
    Blay JY
    Cancer Treat Rev; 2011 Aug; 37(5):373-84. PubMed ID: 21195552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
    Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
    J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.